Scott Tarriff Net Worth

The estimated Net Worth of Scott Tarriff is at least $34.3 Milione dollars as of 1 November 2023. Mr. Tarriff owns over 21,619 units of Eagle Pharmaceuticals Inc stock worth over $2,034,517 and over the last 12 years he sold EGRX stock worth over $24,367,037. In addition, he makes $7,883,700 as Chief Executive Officer e Director at Eagle Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Tarriff EGRX stock SEC Form 4 insiders trading

Scott has made over 21 trades of the Eagle Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 21,619 units of EGRX stock worth $299,207 on 1 November 2023.

The largest trade he's ever made was selling 135,710 units of Eagle Pharmaceuticals Inc stock on 20 March 2015 worth over $6,288,801. On average, Scott trades about 14,476 units every 58 days since 2013. As of 1 November 2023 he still owns at least 545,447 units of Eagle Pharmaceuticals Inc stock.

You can see the complete history of Mr. Tarriff stock trades at the bottom of the page.

Scott Tarriff biography

Scott L. Tarriff serves as Chief Executive Officer, Director of the Company. Prior to joining Eagle, Mr. Tarriff held various executive positions at Par Pharmaceutical Companies, Inc., a publicly-traded developer, manufacturer and marketer of specialty pharmaceuticals, including as president and chief executive officer from September 2003 to September 2006, after joining Par in 1998. Mr. Tarriff also served on Par's board of directors from 2002 to September 2006. Prior to that, Mr. Tarriff held various positions with Bristol-Myers Squibb, a publicly-traded biopharmaceutical company, including senior director-marketing. Mr. Tarriff has served as a director of Synthetic Biologics, Inc., a publicly-traded biotechnology company, since February 2012 and as a director of Ziopharm Oncology, Inc., a publicly-traded biotechnology company, since September 2015 and previously served on the board of directors of Clinical Data, Inc., a publicly-traded pharmaceutical company, from September 2009 to April 2011 when Clinical Data was acquired by Forest Laboratories, Inc. Mr. Tarriff holds a B.S. in marketing from Pennsylvania State University and an M.B.A. from Rider College.

What is the salary of Scott Tarriff?

As the Chief Executive Officer e Director of Eagle Pharmaceuticals Inc, the total compensation of Scott Tarriff at Eagle Pharmaceuticals Inc is $7,883,700. There are no executives at Eagle Pharmaceuticals Inc getting paid more.

How old is Scott Tarriff?

Scott Tarriff is 61, he's been the Chief Executive Officer e Director of Eagle Pharmaceuticals Inc since 2017. There are 3 older and 7 younger executives at Eagle Pharmaceuticals Inc. The oldest executive at Eagle Pharmaceuticals Inc is Steven Ratoff, 77, who is the Independent Director.

What's Scott Tarriff's mailing address?

Scott's mailing address filed with the SEC is C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD, SUITE 315, WOODCLIFF LAKE, NJ, 07677.

Insiders trading at Eagle Pharmaceuticals Inc

Over the last 11 years, insiders at Eagle Pharmaceuticals Inc have traded over $188,911,314 worth of Eagle Pharmaceuticals Inc stock and bought 1,029,065 units worth $16,655,732 . The most active insiders traders include Executive Capital Lphec Man..., Douglas L Braunstein e Investments Iv, L.P.Pro Que.... On average, Eagle Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $193,721. The most recent stock trade was executed by Scott Tarriff on 1 November 2023, trading 21,619 units of EGRX stock currently worth $299,207.

What does Eagle Pharmaceuticals Inc do?

specialty pharmaceutical company

Complete history of Mr. Tarriff stock trades at Eagle Pharmaceuticals Inc, Alaunos Therapeutics Inc e Theriva Biologics Inc

Eagle Pharmaceuticals Inc executives and stock owners

Eagle Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Scott Tarriff,
  Chief Executive Officer, Director
• David Pernock,
  President, Chief Operating Officer
• David M. Pernock,
  Exec. VP of Operations
• Brian Joseph Cahill,
  Chief Financial Officer
• Michael Graves,
  Independent Chairman of the Board
• Steven Ratoff,
  Independent Director
• Robert Glenning,
  Independent Director
• Jennifer Simpson,
  Independent Director
• Richard Edlin,
  Independent Director
• Lisa Wilson,
  IR Contact Officer
• Brian Cahill,
  Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
• Debra M. Hussain,
  Sr. VP & Head of Commercial
• Reiner Nowak,
  Exec.
• Dr. Gaozhong Zhu Ph.D.,
  Sr. VP of Pharmaceutical Devel.
• Dr. Valentin R. Curt M.D.,
  Sr. VP of Clinical Drug Devel.
• John Kimmet,
  Exec. VP of Marketing Oncology & Acute Care
• Michael Shawn Moran,
  Exec. VP, Chief Commercial Officer & Principal Operating Officer
• Daniel O'Connor,
  Exec. VP, Chief Strategy Officer & Head of Corp. Devel.
• Ryan Debski,
  Exec. VP, Gen. Counsel & Chief Compliance Officer
• Steven L. Krill,
  Chief Scientific Officer
• Pete A. Meyers,
  Chief Financial Officer
• David E Riggs,
  Chief Financial Officer
• Investments Iv, L.P.Pro Que...,
  
• Sander A Flaum,
  Director
• Douglas L Braunstein,
  Director
• Executive Capital Lphec Man...,
  
• Alain Schreiber,
  Director
• Jay Moorin,
  Director
• Management Llc Pro Quest In...,
  
• Financial Llc Pro Quest Inv...,
  
• Paul Bruinenberg,
  Chief Medical Officer
• Associates Iv Llc Pro Quest...,
  
• Judith Ng Cashin,
  Chief Medical Officer
• Luciana Borio,
  Director
• Michael Shawn Moran,
  EVP, Chief Commercial Officer